Business Context and Reporting Period
Company: Metagenomi Therapeutics, Inc. (formerly Metagenomi, Inc.)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: An in vivo genome editing company developing curative genetic medicines using proprietary metagenomics-derived technologies. The company focuses on site-specific genome integration, base editing, and RNA/DNA-mediated integration systems.
Strategic Shift: In late 2025, the company announced a strategic reprioritization to focus resources on its lead program, MGX-001 (Hemophilia A), and later-stage preclinical pipeline. This included a 25% workforce reduction and a change in leadership, with Jian Irish, Ph.D., M.B.A., promoted to CEO.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $25,210 | $52,295 |
| Total Operating Expenses | $121,223 | $141,196 |
| Net Loss | $(87,868) | $(78,058) |
| Cash, Cash Equivalents, and Marketable Securities | $160,800 | $248,307 |
| Accumulated Deficit | $(310,870) | $(223,002) |
| Net Cash Used in Operating Activities | $(88,892) | $(109,073) |
Note: The company has no product sales revenue. All revenue is derived from collaboration agreements (primarily Ionis Pharmaceuticals).
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $27.1 million (52%) to $25.2 million. This was primarily due to the termination of the Moderna agreement in 2024 (which accelerated revenue recognition in the prior year) and timing differences in the Ionis agreement.
- Expense Reduction: Total operating expenses decreased by $20.0 million (14%) to $121.2 million. Research and Development (R&D) expenses dropped $14.7 million, and General and Administrative (G&A) expenses dropped $5.2 million, largely driven by the 25% workforce reduction and lower stock-based compensation.
- Investment Losses: The company recognized a $1.3 million loss on the change in fair value of its investment in Affini-T Therapeutics, Inc., compared to a $9.2 million loss in 2024. The Affini-T agreement was terminated in September 2025 due to Affini-T's assignment for the benefit of creditors.
- Liquidity Position: Cash and marketable securities decreased by approximately $87.5 million year-over-year, though the company maintains a runway of at least 12 months as of the filing date.
Guidance, Outlook, and Risks
Outlook and Pipeline
- MGX-001 (Hemophilia A): The lead program demonstrated curative Factor VIII activity in non-human primates (NHPs) in November 2025. The company completed a pre-IND meeting in Q4 2025 and targets an IND submission in Q4 2026, with clinical trials expected to initiate in 2027.
- Ionis Collaboration: The company is in Wave 1 of its collaboration with Ionis, focusing on four cardiometabolic targets (including APOC3, TTR, and AGT). All targets are in the lead optimization phase.
- Financial Runway: Management estimates existing cash and marketable securities ($160.8 million) are sufficient to fund operations for at least the next 12 months. Additional funding will be required to advance clinical trials and commercialization.
Risks and Contingencies
- Profitability: The company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future. It has never generated revenue from product sales.
- Legal Proceedings: A securities class action lawsuit (Vreeland v. Metagenomi Inc. et al.) is pending, alleging misleading statements regarding the Moderna collaboration. The company intends to defend vigorously but cannot estimate potential losses.
- Capital Needs: Future funding requirements depend on clinical trial progress. Failure to raise additional capital could force delays or termination of development programs.
- Regulatory Uncertainty: As an early-stage company with no approved products, the company faces significant regulatory risks regarding the novel nature of its genome editing technology.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $160.8 million cash balance against the projected burn rate, especially given the planned IND submission in late 2026 and clinical trials in 2027.
- MGX-001 Clinical Timeline: Monitor the Q4 2026 IND submission target and the 2027 clinical trial initiation date for any delays.
- Ionis Collaboration Milestones: Track progress on the four Wave 1 targets and the potential for Ionis to select Wave 2 targets, which would trigger additional fees.
- Legal Exposure: Review the status of the Vreeland securities class action lawsuit for any updates on the motion to dismiss or settlement discussions.
- Workforce Stability: Assess the impact of the 25% workforce reduction and CEO transition on the company's ability to execute its streamlined development strategy.